Evolving Patterns and Unmet Needs in the TB Population in Developing and Developed Markets
Decision Resources, Inc, October 2011
The combination of animal-human transmission, opportunistic infection in AIDS patients, and rapid urbanization has led to sharp increases in tuberculosis (TB) cases in many parts of the world. Although the number of TB cases will decline over the coming decade as public health improves and the use of HAART (highly active antiretroviral therapy) becomes more widespread, TB will continue to be a public health concern and multidrug resistance a continuing problem in its treatment.
Questions answered in this report:
- After many years of a sharply increasing risk of TB in many developing countries— particularly those with a high prevalence of HIV infection—and a persistent endemic level in many developed countries, the number of TB cases has recently begun to decline. What are the contributing factors behind the recent decline in TB cases? Will this decline continue?
- The choice of drug regimen is often dictated by national or international guidelines, particularly for treatment of drug-susceptible disease, for which all commonly used drugs are available in generic form. How do the various guidelines compare in terms of the recommended drug regimens? Is a particular drug regimen typically recommended for either drug-susceptible or drug-resistant disease?
Scope:
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan, Brazil, China, India, Russia, and South Africa.
Patient populations: Total number of diagnosed incident cases of active TB per year in each pharmaceutical market. The following subpopulations are also forecast: HIV-associated cases of TB, extrapulmonary cases of TB, multidrug-resistant cases of TB, and extensively drug-resistant cases of TB (in countries where extensively drug-resistant TB is a significant clinical entity).
Epidemiological forecast: The report forecasts all of the patient populations over the period 2010-2020. For China and India, patients are stratified by populations by urban or rural status to account for the different levels of risk and patterns of transmission in urban and rural populations, and the report considers how the ongoing urbanization of those countries will affect overall disease risk.
Medical practice: Systematic review and comparison of guidelines for the treatment of active TB in the countries considered in this report.
Drug resistance: Evaluation of both drug-resistant disease and drug toxicity as areas of unmet need, including our forecast of cases of multidrug-resistant and extensively drug-resistant TB over the period 2010-2020.
Executive Summary
Strategic Considerations
Introduction
Epidemiology
Diagnosed Incident Cases
- Brazil
- China
- India
- Russia
- South Africa
- Developed Countries
HIV-Associated Cases
Extrapulmonary TB Cases
Medical Practice
Drug Resistance
Drug Toxicity
Appendix A: Bibliography
About the Author
- Akorn
- Bayer/Merck
- Chao Center
- Johnson & Johnson
- Pfizer
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
